Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

<< Previous

Bullboard Posts

Next >>

Post by biotraderpro1on Feb 25, 2021 11:13am

339 Views

Post# 32657879

Worth of HEM

Just a bit too quiete on this board.

I think everyone is patiently waiting the results ( and run up before results ). Once we start getting closer to the announcement that they have completed ( March 31 anticipated) we should see a gradual increase in stock price (IMO) all the way to the results being released in late April or early May.

Has there been a better time to be a shareholder in this stock than right now ? I don't think so.

GLTA

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for June 3, 2024